Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
50.25    -4.00 (-7.55%)
Bid:
49.50
Ask:
51.00
Spread: 1.50 (3.03%)
Market Cap: £94.01m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Production Update

14 Apr 2014 07:00

RNS Number : 7271E
Iofina PLC
14 April 2014
 

 

 

14 April 2014

 

IOFINA PLC

("Iofina" or the "Company")

(LSE AIM: IOF)

 

 

Commencement of Production at IO#4 and IO#5

 

Iofina, specialists in the exploration and production of iodine and iodine specialty chemical derivatives, is pleased to announce receipt of notification for the federal regulatory approval required to produce iodine at the Company's recently completed IO#4 and IO#5 iodine production plants. Production operations commenced immediately upon such approval on 11 April 2014.

 

In line with the Company's statement on 27 March, construction of the Company's IO#6 plant continues, with completion expected to occur in Q2 2014. Images relating to IO#6's progress can be viewed at www.iofina.com.

 

The Company will provide shareholders with an update on its first quarter when it releases its results for the year ended 31st December 2013, scheduled for the week commencing 21 April.

 

Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America based on Iofina's WET® and IOsorb™ technology.

 

George Lantz, CEO and President of the Company, commented: "Our production teams have already started full-scale production operations at both plants and are pleased to be producing iodine at these state-of-the-art facilities. This brings the number of plants currently in operation and online to five plants, a 150 per cent increase over the fourth quarter 2013."

 

For further information, please contact:

George Lantz, CEO

Iofina

Tel: +44 (0)20 3006 3135

www.iofina.com

 

John Prior/Rupert Krefting/Huw Jeremy

Numis Securities

Tel: +44 (0)20 7260 1000

 

Rob Collins

GMP Securities

Tel: +44(0)20 7647 2800

 

Media Contact:

Dominic Barretto/Anna Legge

Yellow Jersey PR

Tel: +44 (0)7768 537 739

 

About Iofina:

Iofina specializes in the exploration and production of iodine, iodine specialty chemical derivatives and produced water. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America based on Iofina's WET® IOsorb™ technology. Iofina has iodine production operations in the United States, specifically in Texas, Montana and Oklahoma. It has complete vertical integration from the production of iodine in the field to the manufacture of the chemical end-products derived from iodine to the consumer and the recycling of iodine using iodinated side-streams from waste chemical processes in Europe, North America and Asia. Iofina utilises its portfolio of patented and patent pending technology, proprietary methods and trademarks throughout all business lines.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DRLGMGMDKFRGDZM
Date   Source Headline
23rd Sep 20214:35 pmRNSPrice Monitoring Extension
22nd Sep 20219:58 amRNSHolding(s) in Company
10th Sep 20214:15 pmRNSHolding(s) in Company
10th Sep 20213:25 pmRNSHolding(s) in Company
15th Jul 20217:00 amRNSH1 2021 Update
18th Jun 20214:36 pmRNSPrice Monitoring Extension
18th Jun 20213:20 pmRNSResult of AGM
27th May 20214:40 pmRNSSecond Price Monitoring Extn
27th May 20214:36 pmRNSPrice Monitoring Extension
27th May 20212:06 pmRNSSecond Price Monitoring Extn
27th May 20212:00 pmRNSPrice Monitoring Extension
27th May 202111:06 amRNSSecond Price Monitoring Extn
27th May 202111:00 amRNSPrice Monitoring Extension
27th May 20217:00 amRNSHolding(s) in Company
25th May 20217:00 amRNSAnnual Financial Report
21st May 20215:50 pmRNSNotice of Results
15th Apr 20217:00 amRNSQ1 2021 Update
1st Mar 20215:36 pmRNSDirector/PDMR Shareholding
24th Feb 20217:00 amRNSDirector/PDMR Shareholding
19th Feb 20217:00 amRNSDirector/PDMR Shareholding
19th Jan 20217:00 amRNSMarket Update
22nd Dec 20204:41 pmRNSSecond Price Monitoring Extn
22nd Dec 20204:35 pmRNSPrice Monitoring Extension
22nd Dec 20202:05 pmRNSSecond Price Monitoring Extn
22nd Dec 20202:00 pmRNSPrice Monitoring Extension
16th Dec 202011:50 amRNSGrant of Share Options
16th Oct 20207:00 amRNSQ3 2020 Update
13th Oct 20204:40 pmRNSSecond Price Monitoring Extn
13th Oct 20204:35 pmRNSPrice Monitoring Extension
29th Sep 20207:00 amRNSINTERIM RESULTS
23rd Sep 20207:09 amRNSPrice Monitoring Extension
23rd Sep 20207:07 amRNSSecond Price Monitoring Extn
23rd Sep 20207:04 amRNSPrice Monitoring Extension
23rd Sep 20207:01 amRNSSecond Price Monitoring Extn
22nd Sep 20204:41 pmRNSSecond Price Monitoring Extn
22nd Sep 20204:36 pmRNSPrice Monitoring Extension
22nd Sep 20202:05 pmRNSSecond Price Monitoring Extn
22nd Sep 20202:00 pmRNSPrice Monitoring Extension
22nd Sep 20207:00 amRNSDebt Refinancing Signed
26th Aug 20207:00 amRNSDebt Update
31st Jul 20208:00 amRNSLaunch of new website
22nd Jul 202011:06 amRNSSecond Price Monitoring Extn
22nd Jul 202011:00 amRNSPrice Monitoring Extension
22nd Jul 20207:00 amRNSCorporate Update
30th Jun 20202:36 pmRNSDebt Update
30th Jun 202011:52 amRNSResult of AGM
26th Jun 20201:26 pmRNSChange of venue for AGM on 30 June 2020
26th Jun 20207:00 amRNSIO#8 and Debt Update
27th May 20207:00 amRNSFinal Results
19th May 20204:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.